financetom
Business
financetom
/
Business
/
Raymond James Q2 profit rises on strong capital markets performance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Raymond James Q2 profit rises on strong capital markets performance
Apr 24, 2024 3:44 PM

April 24 (Reuters) - Raymond James on Wednesday

posted a 11% rise in second-quarter adjusted profit, powered by

strong performance in its capital markets business on the back

of a rebound in mergers and acquisitions.

After a two-year dry spell, global M&A activity bounced back

this year, on expectations of potential interest rate cuts and a

rally in the equity markets.

Total M&A volumes globally climbed 30% to about $755.1

billion in the first quarter, according to the most recent data

from Dealogic.

Revenue in the capital markets unit jumped 6% to $321

million in the January-to-March quarter, driven by a rebound in

investment banking, which increased to $171 million from $145

million in the year ago period.

Wall Street heavyweight and larger peer Morgan Stanley ( MS )

beat estimates for first-quarter profit last week, helped

by a resurgence in investment banking and wealth management.

Raymond James' asset management revenue rose 17% in the

reported quarter to $252 million.

Adjusted net income available to common shareholders was

$494 million, or $2.31 per share, in the three months ended

March 31, compared with $446 million, or $2.03 per share, a year

earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kalaris Posts Positive Results from Macular Degeneration Drug Trial
Kalaris Posts Positive Results from Macular Degeneration Drug Trial
Mar 10, 2026
05:50 PM EST, 12/17/2025 (MT Newswires) -- Kalaris Therapeutics ( KLRS ) reported late Wednesday positive initial data from its Phase 1a trial of its investigational drug for treating naive neovascular AMD patients. The single ascending dose (SAD) trial showed the drug candidate, TH103, had clinically meaningful improvements in vision and retinal anatomy. The trial also indicated early signs of...
DoorDash, OpenAI Partner to Offer Grocery Shopping App Inside ChatGPT
DoorDash, OpenAI Partner to Offer Grocery Shopping App Inside ChatGPT
Mar 10, 2026
05:47 PM EST, 12/17/2025 (MT Newswires) -- DoorDash ( DASH ) has teamed up with Microsoft ( MSFT )-backed OpenAI (MSFT) to offer a grocery-shopping app directly within ChatGPT, allowing users to convert recipes into food orders delivered from nearby stores. The partnership marks a shift toward agentic commerce, with AI acting as a personal assistant to handle shopping, payments,...
FCC deletes reference to agency independence during US Senate hearing
FCC deletes reference to agency independence during US Senate hearing
Mar 10, 2026
(Adds comments by Trump, details, paragraphs 7-8 and 13, changes story identification tag used by some clients) * FCC website changed after questioning on agency's independence * Senator Lujan challenges FCC's independence claim * Trump's executive order restricts FCC's regulatory process By David Shepardson WASHINGTON, Dec 17 (Reuters) - The Federal Communications Commission on Wednesday deleted a longstanding reference to...
BP Appoints Meg O'Neill as Chief Executive Officer
BP Appoints Meg O'Neill as Chief Executive Officer
Mar 10, 2026
05:54 PM EST, 12/17/2025 (MT Newswires) -- BP (BP) said late Wednesday it appointed Meg O'Neill as chief executive officer, starting April 1, 2026. O'Neill will succeed Murray Auchincloss, who will step down as CEO and board director on Dec. 18. Auchincloss will continue in an advisory role until December 2026 to support the transition. Carol Howle, executive vice president...
Copyright 2023-2026 - www.financetom.com All Rights Reserved